Literature DB >> 8384265

Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small-cell lung carcinoma.

P D Brown1, R E Bloxidge, N S Stuart, K C Gatter, J Carmichael.   

Abstract

BACKGROUND: Matrix metalloproteinases, in particular the 92-kd and 72-kd gelatinases, have been implicated in the progression of breast, colorectal, and gastric carcinomas, but involvement of the gelatinases in progression of non-small-cell lung carcinoma has not been documented. Immunohistochemical studies have measured the overall expression of these enzymes in tumor tissue but have failed to determine the proportion of active enzyme to latent proenzyme. Because the conversion of the latent proenzyme to active enzyme results in removal of a 10-kd amino-terminal domain, the expression of each proteinase can be determined by zymography, which separates substances according to molecular weight.
PURPOSE: The purpose of this study was to examine the expression and activation of 92-kd and 72-kd proenzymes in non-small-cell lung carcinoma.
METHODS: Gelatin zymography was used to study the expression of 92-kd and 72-kd gelatinases in 22 samples of non-small-cell lung carcinoma and adjacent uninvolved tissue. Medium conditioned by human RPMI-7951 melanoma cells was used as a marker for the 72-kd proenzyme, and medium conditioned by concanavalin A-treated human HT-1080 fibrosarcoma cells was used as a marker for both the 92-kd proenzyme and the 62-kd activated form of the 72-kd proenzyme.
RESULTS: Both 92-kd and 72-kd proenzymes were expressed to varying degrees in the samples studied. The 82-kd activated form of the 92-kd proenzyme was detected in eight tumor samples but in none of the matched uninvolved tissues. Expression of the 62-kd activated form of the 72-kd proenzyme ranged from a strong band in the tumor tissue, with little or none detectable in the adjacent uninvolved tissue, to the presence of only trace amounts of enzyme in both tumor and uninvolved tissue. There was, however, a highly significant statistical association between the level of expression of the 62-kd activated enzyme in the tumor tissue and evidence of tumor spread (P = .001).
CONCLUSION: These results demonstrate elevated expression of the activated forms of both the 92-kd and 72-kd proenzymes in non-small-cell lung carcinoma tissue relative to adjacent uninvolved tissue. IMPLICATION: These results indicate that non-small-cell lung carcinoma should be considered as a possible target for metalloproteinase inhibitory therapy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8384265     DOI: 10.1093/jnci/85.7.574

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  57 in total

1.  MMP-9 secretion and MMP-2 activation distinguish invasive and metastatic sublines of a mouse mammary carcinoma system showing epithelial-mesenchymal transition traits.

Authors:  A M Tester; N Ruangpanit; R L Anderson; E W Thompson
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

Review 2.  The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer.

Authors:  G Cox; W P Steward; K J O'Byrne
Journal:  Thorax       Date:  1999-02       Impact factor: 9.139

3.  Pharmacokinetics and safety assessments of high-dose and 4-week treatment with S-3304, a novel matrix metalloproteinase inhibitor, in healthy volunteers.

Authors:  Timothy G K Mant; Daniel Bradford; Dipti M Amin; Jaya Pisupati; Yoshikazu Kambayashi; Yoshitaka Yano; Kazushige Tanaka; Takuko Yamada-Sawada
Journal:  Br J Clin Pharmacol       Date:  2006-10-31       Impact factor: 4.335

4.  Expression of metalloproteinases endometrial stromal sarcoma: immunohistochemical study using image analysis.

Authors:  P Liokumovich; I Goldberg; B Davidson; W H Gotlieb; T Zahavi; G Ben-Baruch; I Reder; J Kopolovic
Journal:  J Clin Pathol       Date:  1999-03       Impact factor: 3.411

Review 5.  Matrix metalloproteinase inhibitors: present achievements and future prospects.

Authors:  L J Denis; J Verweij
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

Review 6.  The matrix metalloproteinases and their inhibitors in pancreatic cancer. From molecular science to a clinical application.

Authors:  S R Bramhall
Journal:  Int J Pancreatol       Date:  1997-02

7.  Relationship between matrix metalloproteinase 2 and lung cancer progression.

Authors:  Chun-Bao Guo; Shan Wang; Chun Deng; Dian-Liang Zhang; Fu-Ling Wang; Xian-Qing Jin
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

8.  Proteolytic processing of membrane-type-1 matrix metalloproteinase is associated with gelatinase A activation at the cell surface.

Authors:  K Lehti; J Lohi; H Valtanen; J Keski-Oja
Journal:  Biochem J       Date:  1998-09-01       Impact factor: 3.857

9.  Comparative expression of matrix metalloproteinases in low-grade mucoepidermoid carcinoma and typical lung cancer.

Authors:  Jiang Fan; Feng-Ying Wu; Lei Wang; Ge-Ning Jiang; Wen Gao
Journal:  Oncol Lett       Date:  2011-08-18       Impact factor: 2.967

10.  KAI1 is a potential target for anti-metastasis in pancreatic cancer cells.

Authors:  Jian-Hua Xu; Xiao-Zhong Guo; Li-Nan Ren; Li-Chun Shao; Min-Pei Liu
Journal:  World J Gastroenterol       Date:  2008-02-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.